Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low100.00 05/09/17
52 week change -9.00 (-5.81%)
4 week volume1,592,513 24/08/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva) Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all primary and secondary ef...

Verona Pharma Appoints Stifel as Nominated Adviser

Director Deals - Verona Pharma PLC (VRP)

Dr David Ebsworth, Chairman, bought 8,130 shares in the company on the 17th August 2017 at a price of 122.50p. The Direc...

PDMR Dealing

Notification of issuers, persons discharging managerial responsibilities and their connected persons in respect of transactions conducted in their own account in shares of the issuer

Verona Pharma losses widen as it starts clinical trials

Verona Pharma (VRP), a clinical-stage biopharmaceutical company, made a loss after tax of 5.1 million in the first half, co...

Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update

Announcement of half-year/second quarter financial results

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

Miscellaneous medium priority announcements

Verona to present at healthcare conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the 2017 W...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: Stifel - ignore

    Sorry folks, wrong board ;-)
    12-Sep-2017
    paulmc1
  • Stifel

    Stifel has increased its trade size to 250,000 from 100,000, joining Singer (also our joint broker) while all the other market makers remain at 100,000. Stifel has also been on ...
    12-Sep-2017
    paulmc1
  • Conference call

    slides available http://www.veronapharma.com/uploads/downloads/rpl554-3-day-add-on-study-sept-2017-final-1504765345.pdf mol
    8-Sep-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.20%
RENEURON10%
GULF KEYSTONE10%
BP10%
RANGE RES.10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP